Stereotaxis Surpasses 75,000 Procedures With Remote Magnetic Navigation System
06 January 2015 - 11:30AM
Stereotaxis, Inc. (Nasdaq:STXS), a leading provider of innovative
technologies for the treatment of cardiac arrhythmias, announced
today that more than 75,000 patient cases have been completed with
its remote magnetic navigation technology. The Company also
announced that it will present the latest enhancements and clinical
data for its industry leading robotic platform at the upcoming
International AF Symposium, January 8-10, 2015 in Orlando, FL
(Booth #816). Now in its 20th year, the annual three-day symposium
brings together the world's leading medical scientists and
providers to discuss the most recent advances in the field of
atrial fibrillation.
First commercialized in 2003, Stereotaxis remote magnetic
navigation technology is designed for the safe, effective and
efficient facilitation of complex cardiac ablation. The Company's
fourth generation remote navigation system, the Niobe® ES system,
was launched in December 2011 and, together with its Vdrive®
robotic navigation system and Odyssey™ solutions portfolio,
comprises the Epoch™ Solution, a fully remote electrophysiology
(EP) platform. Today, the Niobe system is installed in 177 EP sites
worldwide and supported by over 200 peer-reviewed publications.
"The expanding experiential and clinical body of evidence
continues to confirm the outstanding performance of our Epoch
platform in safety, procedure efficiency and outcomes," said
William C. Mills, Stereotaxis Chief Executive Officer. "We are
excited to advance the dialogue with the International AF Symposium
participants concerning the immediate and long-term efficacy of our
system in treating complex arrhythmias through ablation
therapy."
During a Product Theatre lunch session on January 8, Stereotaxis
physician users will discuss how Stereotaxis' latest advancements
are improving the success of their ablation programs. Moderated by
Dr. Andrea Natale, Executive Director for the Texas Cardiac
Arrhythmia Institute at St. David's Medical Center in Austin, TX,
the afternoon's presenters include Dr. David Burkhardt (Texas
Cardiac Arrhythmia Institute), Dr. William Spear (Advocate Christ
Medical Center, Oak Lawn, IL) and Dr. Erik Wissner (Asklepios
Klinik St. Georg, Hamburg, Germany).
About Stereotaxis
Stereotaxis is a healthcare technology and innovation leader in
the development of robotic cardiology instrument navigation systems
designed to enhance the treatment of arrhythmias and coronary
disease, as well as information management solutions for the
interventional lab. Over 100 issued patents support the Stereotaxis
platform, which helps physicians around the world provide
unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. Stereotaxis' core Epoch™ Solution
includes the Niobe® ES remote magnetic navigation system, the
Odyssey® portfolio of lab optimization, networking and patient
information management systems and the Vdrive™ robotic navigation
system and consumables.
The core components of Stereotaxis systems have received
regulatory clearance in the U.S., European Union, Canada, China,
Japan and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™
variable loop catheter manipulator and V-CAS™ catheter advancement
system have received U.S. clearance. For more information, please
visit www.stereotaxis.com.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words
"believe," "estimate," "project," "expect" or similar expressions.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's ability to raise additional capital on a timely basis and
on terms that are acceptable, its ability to continue to manage
expenses and cash burn rate at sustainable levels, its ability to
continue to work with lenders to extend, repay or refinance
indebtedness on acceptable terms, continued acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, competitive
factors, changes resulting from the recently enacted healthcare
reform in the U.S., including changes in government reimbursement
procedures, dependence upon third-party vendors, timing of
regulatory approvals, and other risks discussed in the Company's
periodic and other filings with the Securities and Exchange
Commission. By making these forward-looking statements, the Company
undertakes no obligation to update these statements for revisions
or changes after the date of this release. There can be no
assurance that the Company will recognize revenue related to its
purchase orders and other commitments in any particular period or
at all because some of these purchase orders and other commitments
are subject to contingencies that are outside of the Company's
control. In addition, these orders and commitments may be revised,
modified, delayed or canceled, either by their express terms, as a
result of negotiations, or by overall project changes or
delays.
CONTACT: Investor Contact:
Martin Stammer
Chief Financial Officer
314-678-6155
Investor Contact:
Todd Kehrli / Jim Byers
MKR Group, Inc.
323-468-2300
stxs@mkr-group.com